Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GL-320
- Development stage
- Preclinical
- Lead developer
- Wayne State University
- Modality
- Small Molecules
01
Overview
GL-320 is a potent and selective small-molecule inhibitor of the deubiquitinating enzyme USP10. Developed by researchers at Wayne State University, it is being investigated for its potential to overcome resistance to platinum-based chemotherapy and enhance the efficacy of immunotherapy in non-small cell lung cancer (NSCLC). By inhibiting USP10, GL-320 destabilizes multiple DNA damage response (DDR) and pro-survival proteins, leading to impaired DNA repair, cell cycle arrest, and the induction of autophagy and caspase-dependent apoptosis. Furthermore, GL-320 triggers immunogenic cell death (ICD), characterized by endoplasmic reticulum stress and the exposure of calreticulin, which may stimulate anti-tumor immunity.
Beyond the preview
Go deeper on GL-320.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GL-320.